IP Library Patent Application 15398207
Patent Application
App. No. 15/398,207

DIRECTLY COMPRESSIBLE GRANULAR MICROCRYSTALLINE CELLULOSE BASED EXCIPIENT, MANUFACTURING PROCESS AND USE THEREOF

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/398,207
Abstract

An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties, excellent/high compactibility, and increased API loading and blendability as compared to the individual components, and as compared to conventional excipients formed from the same materials. The improved excipient has strong intraparticle bonding bridges between the components, resulting in a unique structural morphology including significant open structures or hollow pores. The presence of these pores provides a surface roughness that is the ideal environment for improved blending with an API.

Claims (130)

1 . A composition comprising:

about 90% to about 99% microcrystalline cellulose; and

about 1% to about 10% at least one binder;

wherein the microcrystalline cellulose and binder are indistinguishable when viewed with a SEM, thereby forming substantially homogeneous-particles.

2 . The composition of claim 1 wherein the composition includes:

about 95% to about 99% microcrystalline cellulose; and

about 1% to about 5% at least one binder.

3 . The composition of claim 1 wherein the composition includes:

about 97% to about 99% microcrystalline cellulose; and

about 1% to about 3% at least one binder.

4 . The composition of claim 1 wherein the binder includes hydroxypropyl methylcellulose.

5 . The composition of claim 1 wherein the excipient is formed by homogenizing/spray dry granulating an aqueous slurry comprised of the microcrystalline cellulose and binder.

6 . The composition of claim 1 wherein the aerated bulk density is 0.2-0.3 g/cc.

7 . A method or making an excipient comprising:

mixing a microcrystalline cellulose (MCC) slurry with a cross-linked polyvinylpyrrolidone slurry to form a MCC/cross-linked polyvinylpyrrolidone slurry;

mixing a binder comprising hydroxypropyl methylcellulose in water to form a viscous hydroxypropyl methylcellulose slurry;

homogenizing the hydroxypropyl methylcellulose slurry with the MCC/cross-linked polyvinylpyrrolidone slurry to form a homogenized slurry; and

spray dry granulating the homogenized slurry through a rotary nozzle at an RPM of between 12,000 and 25,000 to form substantially homogeneous and substantially spherical particles of excipient wherein the microcrystalline cellulose and hydroxypropyl methylcellulose are indistinguishable when viewed with a SEM, and wherein said excipient is a complete and universal directly compressible excipient with a flowability index over 80.

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . pharmaceutical tablet comprising:

at least one active pharmaceutical ingredient;

a disintegrant; and

an excipient of substantially homogeneous particles including:

a) microcrystalline cellulose; and

b) at least one binder.

17 . The tablet of claim 16 wherein the excipient includes:

about 90% to about 99% microcrystalline cellulose; and

about 1% to about 10% at least one binder.

18 . The tablet of claim 16 wherein the excipient includes:

about 95% to about 99% microcrystalline cellulose; and

about 1% to about 5% at least one binder.

19 . The tablet of claim 16 wherein the excipient includes:

about 97% to about 99% microcrystalline cellulose; and

about 1% to about 3% at least one binder.

20 . The tablet of claim 16 wherein the binder includes hydroxypropyl methylcellulose.

21 . A method of making a pharmaceutical tablet comprising:

mixing at least one active pharmaceutical ingredient with a disintegrant and an excipient of substantially homogeneous particles including:

a) microcrystalline cellulose; and

b) at least one binder; and

compressing the mixture to form a tablet.

22 . The method of claim 21 wherein the excipient includes:

about 90% to about 99% microcrystalline cellulose; and

about 1% to about 10% at least one binder.

23 . The method of claim 21 wherein the excipient includes:

about 95% to about 99% microcrystalline cellulose; and

about 1% to about 5% at least one binder.

24 . The method of claim 21 wherein the excipient includes:

about 97% to about 99% microcrystalline cellulose; and

about 1% to about 3% at least one binder.

25 . The method of claim 21 wherein the binder includes hydroxypropyl methylcellulose.

26 . A composition comprising:

about 75% to about 98% microcrystalline cellulose;

about 1% to about 10% at least one binder; and

about 1% to about 20% at least one disintegrant;

wherein the microcrystalline cellulose, binder and disintegrant are indistinguishable when viewed with a SEM, thereby forming substantially homogeneous, substantially spherical particles.

27 . The composition of claim 26 wherein the composition includes:

about 80% to about 90% microcrystalline cellulose;

about 2% to about 8% at least one binder; and

about 3% to about 12% at least one disintegrant.

28 . The composition of claim 26 wherein the composition includes:

about 85% to about 93% microcrystalline cellulose;

about 2% to about 5% at least one binder; and

about 10% at least one disintegrant.

29 . The composition of claim 26 wherein the binder includes hydroxypropyl methylcellulose and the disintegrant includes cross-linked polyvinylpyrrolidone.

30 . The composition of claim 26 wherein the excipient is formed by spraying an aqueous slurry comprised of the microcrystalline cellulose, binder and disintegrant.

31 . A method of making an excipient comprising:

mixing a MCC slurry with a disintegrant slurry to form a MCC/disintegrant slurry; mixing a binder in water to form a viscous binder slurry;

homogenizing the binder slurry with the MCC/disintegrant slurry to form a homogenized slurry; and

spray dry granulating the homogenized slurry to form substantially homogeneous, substantially spherical particles of excipient.

32 . The method of claim 31 wherein:

about 75% to about 98% microcrystalline cellulose;

about 1% to about 10% at least one binder; and

about 1% to about 20% at least one disintegrant.

33 . The method of claim 31 comprising:

about 80% to about 90% microcrystalline cellulose;

about 2% to about 8% at least one binder; and

about 3% to about 12% at least one disintegrant.

34 . The method of claim 31 comprising:

about 85% to about 93% microcrystalline cellulose;

about 2% to about 5% at least one binder; and

about 10% at least one disintegrant.

35 . The method of claim 31 wherein the binder includes hydroxypropyl methylcellulose and the disintegrant includes cross-linked polyvinylpyrrolidone.

36 . (canceled)

37 . The method of claim 7 comprising:

about 75% to about 98% microcrystalline cellulose;

about 1% to about 10% hydroxypropyl methylcellulose; and

about 1% to about 20% cross-linked polyvinylpyrrolidone.

38 . The method of claim 7 comprising:

about 80% to about 90% microcrystalline cellulose;

about 2% to about 8% hydroxypropyl methylcellulose; and

about 3% to about 12% cross-linked polyvinylpyrrolidone.

39 . The method of claim 7 comprising:

about 85% to about 93% microcrystalline cellulose;

about 2% to about 5% hydroxypropyl methylcellulose; and

about 10% cross-linked polyvinylpyrrolidone.

40 . A pharmaceutical tablet comprising:

at least one active pharmaceutical ingredient; and

an excipient of substantially homogeneous, substantially spherical particles including:

a) microcrystalline cellulose;

b) at least one binder; and

c) at least one disintegrant.

41 . The tablet of claim 40 wherein the at least one active pharmaceutical ingredient comprises about 1% to about 50% of the tablet.

42 . The tablet of claim 40 further comprising a glidant, wherein the at least one active pharmaceutical ingredient comprises at least about 50% of the tablet, and wherein the tablet further comprises a glidant.

43 . The tablet of claim 40 wherein the excipient includes:

about 75% to about 98% microcrystalline cellulose;

about 1% to about 10% at least one binder; and

about 1% to about 20% at least one disintegrant.

44 . The tablet of claim 40 wherein the excipient includes:

about 80% to about 90% microcrystalline cellulose;

about 2% to about 8% at least one binder; and

about 3% to about 12% at least one disintegrant.

45 . The tablet of claim 40 wherein the excipient includes:

about 85% to about 93% microcrystalline cellulose;

about 2% to about 5% at least one binder; and

about 10% at least one disintegrant.

46 . The tablet of claim 40 wherein the binder includes hydroxypropyl methylcellulose and the disintegrant includes cross-linked polyvinylpyrrolidone.

47 . The tablet of claim 40 wherein the active pharmaceutical ingredient includes ibuprofen.

48 . The tablet of claim 40 wherein the active pharmaceutical ingredient includes atorvastatin calcium.

49 . A method of making a pharmaceutical tablet comprising:

mixing at least one active pharmaceutical ingredient with an excipient of substantially homogeneous, substantially spherical particles according to claim 26 ; and

compressing the mixture to form a tablet.

50 . The method of claim 49 wherein the tablet is formed by a rotary tabletting machine.

51 . The method of claim 49 further including coating the tablet.

Assignments (3)
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS Recorded Nov 16, 2020
From: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A.
To: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
Reel/Frame 054440/0877 →
SECURITY AGREEMENT Recorded Nov 29, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: THE BANK OF NEW YORK MELLON TRUST COMPANY, N.A., AS NOTES COLLATERAL AGENT
Reel/Frame 044528/0960 →
SECURITY AGREEMENT Recorded Nov 28, 2017
From: AVANTOR PERFORMANCE MATERIALS, LLC; NUSIL TECHNOLOGY LLC; APPLIED SILICONE COMPANY LLC; RELIABLE BIOPHARMACEUTICAL, LLC; THERAPAK, LLC
To: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
Reel/Frame 044811/0400 →